Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Redhill Biopharma (NASDAQ:RDHL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares Recordati Industria Chimica E Farmaceutica and Redhill Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.96 billion	3.97	$450.70 million	$2.39	23.83
Redhill Biopharma	$8.04 million	0.51	-$8.27 million	$1,046.75	0.00

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Redhill Biopharma. Redhill Biopharma is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Redhill Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	N/A	N/A	N/A
Redhill Biopharma	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for Recordati Industria Chimica E Farmaceutica and Redhill Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	2	3.33
Redhill Biopharma	1	0	0	0	1.00

Insider & Institutional Ownership

7.2% of Redhill Biopharma shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Recordati Industria Chimica E Farmaceutica has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.93, meaning that its share price is 393% more volatile than the S&P 500.

Summary

Recordati Industria Chimica E Farmaceutica beats Redhill Biopharma on 6 of the 10 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Redhill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.